Cohort of Patients With Left Ventricular Thrombus: Management and Outcomes in the Direct Oral Anticoagulants Era

Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Aug 25, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how different blood-thinning medications affect patients with a specific heart condition called left ventricular thrombus (LVT), which is a blood clot in the heart's left ventricle. The main goal is to find out if patients treated with newer blood thinners, known as Direct Oral Anticoagulants (DOACs), have fewer bleeding problems compared to those treated with older medications called Vitamin K Antagonists (VKAs).

To participate in this trial, you need to be at least 18 years old and have been diagnosed with LVT through tests like echocardiography, MRI, or CT scans between 2013 and 2020. You also need to have received treatment at a specific hospital. If you join the study, you’ll be monitored to see how well the medications work and whether there are any side effects. This trial is currently recruiting participants, and both men and women can take part. If you’re interested, you must be able to give your consent to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients at least 18 years old at enrolment
• • With a LVT identified at echocardiography, MRI or CT between January 1st, 2013 and July 31st, 2020
• • Treated at least once at the Inselspital or in another site of the Insel Gruppe
• • Able to provide a written informed consent
• Exclusion Criteria:
• • Documented refusal